文献速递细胞病理与分子病理

前分析误差:重要的患者安全风险

Pre-analytic error: A significant patient safety risk.
PubMed 文献 · Cancer Cytopathol · 2018-01-01

细胞病理学辅助检测的快速发展提升了微创标本的临床价值,但也带来新的患者安全风险。前分析因素占病理学误差的大多数,需关注检测申请、标本采集、运输、接收和处理等操作环节。随着分子检测成本与技术复杂度增加及外送集中检测趋势,需采用多团队协作方式改进前分析流程、降低误差风险。

要点

  • 前分析因素是病理学误差的主要来源,需重点关注检测申请至标本处理各操作环节。
  • 辅助分子检测成本与技术复杂度增加,外送集中检测带来额外患者安全风险。
  • 需建立包含所有流程相关方的协作团队模式以改进前分析流程。

核心结论

  • 前分析因素占病理学误差的大多数,是细胞病理学辅助检测中重要的患者安全风险。
  • 复杂检测系统问题及流程共同责任有助于最小化安全风险。
  • 需采用协作团队模式改进前分析流程、降低误差风险并提升患者安全。

主要发现

  • 过去十年细胞病理学辅助检测显著增长,提升了微创标本的临床价值。
  • 复杂检测格局带来新的患者安全风险。
  • 外送集中参考实验室检测趋势带来额外患者安全风险。

临床怎么用

  • 关注检测申请、标本采集、运输、接收和处理等操作环节以支持质量改进。
  • 采用包含所有流程相关方的协作团队模式改进前分析流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ancillary testing in cytopathology has grown dramatically over the past decade, enhancing the clinical value of cytology specimens obtained via minimally invasive methods. However, a complex testing landscape brings with it new and emerging risks to patient safety. Recognition of complicated systems issues as well as shared responsibility in process ownership can help to minimize safety risks. Because pre-analytic factors account for the majority of errors in pathology, attention to operational steps (test ordering, specimen collection, specimen transport, specimen accessioning, and specimen processing) is critical for successful quality improvement programs. With increasing technical costs and complexity of many ancillary molecular tests, a growing trend toward send-out testing to centralized reference laboratories poses additional patient safety risks. Given these new realities in cytopathology ancillary testing, a collaborative, team-based approach with all process stakeholders is needed to improve pre-analytic processes, reduce error risk, and enhance patient safety.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Heher YK, Chen Y, VanderLaan PA, et al. Pre-analytic error: A significant patient safety risk. Cancer Cytopathol. 2018. PMID: 30156766. doi:10.1002/cncy.22019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。